Q4 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Research analysts at Leerink Partnrs reduced their Q4 2025 EPS estimates for shares of Illumina in a research note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will earn $1.24 per share for the quarter, down from their previous estimate of $1.25. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $4.90 EPS.

Other analysts also recently issued research reports about the stock. Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Leerink Partners lifted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Piper Sandler decreased their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Price Performance

Shares of ILMN opened at $139.08 on Wednesday. The business has a 50-day moving average of $141.62 and a 200-day moving average of $131.98. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market capitalization of $22.06 billion, a price-to-earnings ratio of -13.96 and a beta of 1.11. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 earnings per share.

Institutional Investors Weigh In On Illumina

A number of institutional investors and hedge funds have recently bought and sold shares of ILMN. Everence Capital Management Inc. purchased a new position in Illumina during the fourth quarter worth about $414,000. GAMMA Investing LLC lifted its position in shares of Illumina by 6.1% during the 4th quarter. GAMMA Investing LLC now owns 3,096 shares of the life sciences company’s stock worth $414,000 after buying an additional 177 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its holdings in shares of Illumina by 66.8% in the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company’s stock valued at $1,582,000 after acquiring an additional 4,797 shares in the last quarter. Finally, Tidal Investments LLC increased its position in shares of Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock valued at $580,000 after acquiring an additional 1,226 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.